CASE REPORTS

Nine Cases of Omeprazole Allergy: Cross-Reactivity Between Proton Pump Inhibitors

T Lobera, B Navarro, MD Del Pozo, I González, A Blasco, R Escudero, M Venturini, E Alarcón

Department of Allergy, Hospital San Pedro/San Millán, Logroño, Spain

Abstract

Although rare, anaphylactic reactions induced by proton pump inhibitors have been reported. The presence of cross-reactivity between different members of the group is not clear.

We studied 9 patients with adverse reactions to omeprazole. Clinical symptoms appeared immediately in 8 patients and after 4 hours in 1. Symptoms ranged from urticaria/angioedema in 7 cases to anaphylaxis in 2 cases. Skin prick tests and oral controlled challenge tests with omeprazole, lansoprazole, and pantoprazole were performed.

Skin prick or intradermal tests with omeprazole were positive in 8 patients. Four were also positive to pantoprazole. Prick tests with lansoprazole were always negative. Lansoprazole was administered to all 9 patients, with good tolerance in 8. Only 3 patients were challenged with pantoprazole and developed widespread urticaria.

We present 9 patients with immunoglobulin E–mediated allergy to omeprazole. In most of our cases, lansoprazole proved to be a good alternative treatment.

Key words: Proton pump inhibitors. Omeprazole. Lansoprazole. Drug allergy. Cross-reactivity.

Introduction

Proton pump inhibitors (PPI), the most potent inhibitors of gastric acid secretion, have revolutionized the treatment of acid-related disorders, including gastroesophageal reflux disease, peptic ulcer disease, and gastropathy induced by nonsteroidal anti-inflammatory drugs (NSAIDs). They are combined with antibiotics to eradicate Helicobacter pylori. Since the introduction of omeprazole, several other PPIs—lansoprazole, rabeprazole, pantoprazole, and esomeprazole—have been developed. They
are generally well tolerated, with minimal adverse effects, most of which are related to the drug’s pharmacokinetic interaction profiles [1]. Although hypersensitivity reactions are rare, several anaphylactic reactions have been reported [2-10]. Some reports describe the presence of cross-reactivity between different members of the group, although no definite pattern has emerged [11-14]. We present 9 patients with omeprazole-induced anaphylactic reactions that were diagnosed by skin tests, oral challenge tests, or both. In order to offer a safe alternative, cross-reactivity studies with lansoprazole and pantoprazole were performed.

**Case Description**

**Patients**

Nine nonatopic women (no history of allergic reaction) aged 35-54 years (mean 42.5 years) were referred to our allergy department with adverse reaction to omeprazole. Clinical symptoms appeared immediately (less than 60 min) in 8 patients and after 4 hours in 1. Symptoms ranged from urticaria/angioedema in 7 cases to anaphylaxis in 2 cases. In 7 cases, the reaction also involved other drugs, which were studied and ruled out. Patient age and the characteristics of the reactions are shown in Table 1. The patients signed a written informed consent form before the skin tests and controlled challenge tests were performed.

**Skin Tests**

Skin prick tests with omeprazole (40 mg/mL), lansoprazole (15-mg tablet), and pantoprazole (20-mg tablet) were performed on the volar side of the forearm, according to published procedures [15]. Reactions were considered positive when a wheal greater than 3 mm in diameter was present 20 minutes later. An intradermal test with omeprazole (1 mg/mL) was performed if the skin prick test was negative. Readings were made 20 minutes after the injection. Results were considered positive when wheals greater than 5 mm were present. Histamine (at 10 mg/mL) was used as a positive control for the skin prick test. Normal saline was used as a negative control for skin prick and intradermal tests.

Ten individuals with no previous history of allergy to proton pump inhibitors and 10 patients with suspected adverse reactions to omeprazole and negative skin prick test results who proved to be tolerant to omeprazole. Skin prick or intradermal tests with omeprazole were positive in 8 patients. Four were also positive to pantoprazole. Prick tests with lansoprazole were always negative. Skin prick tests and intradermal tests were negative in the controls. The results of the skin tests are summarized in Table 2.

**Table 1. Characteristics of the Reactions**

<table>
<thead>
<tr>
<th>Patient Number</th>
<th>Age</th>
<th>Latency</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>50</td>
<td>45 min</td>
<td>Urticaria/angioedema</td>
</tr>
<tr>
<td>2</td>
<td>39</td>
<td>30 min</td>
<td>Urticaria/angioedema</td>
</tr>
<tr>
<td>3</td>
<td>39</td>
<td>60 min</td>
<td>Urticaria</td>
</tr>
<tr>
<td>4</td>
<td>54</td>
<td>4 h</td>
<td>Urticaria</td>
</tr>
<tr>
<td>5</td>
<td>35</td>
<td>45 min</td>
<td>Abdominal pain, sickness,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Urticaria/angioedema</td>
</tr>
<tr>
<td>6</td>
<td>43</td>
<td>60 min</td>
<td>Urticaria/angioedema</td>
</tr>
<tr>
<td>7</td>
<td>36</td>
<td>30 min</td>
<td>Abdominal pain/Urticaria</td>
</tr>
<tr>
<td>8</td>
<td>48</td>
<td>30 min</td>
<td>Urticaria/angioedema</td>
</tr>
<tr>
<td>9</td>
<td>39</td>
<td>30 min</td>
<td>Abdominal pain/Urticaria</td>
</tr>
</tbody>
</table>

**Table 2. Results of the Allergy Study**

<table>
<thead>
<tr>
<th>Patient Number</th>
<th>Skin Tests</th>
<th>Controlled Challenge Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Omeprazole SPT/IDT</td>
<td>Lansoprazole SPT</td>
</tr>
<tr>
<td>1</td>
<td>Positive/NP</td>
<td>Negative</td>
</tr>
<tr>
<td>2</td>
<td>Negative/Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>3</td>
<td>Positive/NP</td>
<td>Negative</td>
</tr>
<tr>
<td>4</td>
<td>Negative/Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>5</td>
<td>Positive/NP</td>
<td>Negative</td>
</tr>
<tr>
<td>6</td>
<td>Positive/NP</td>
<td>Negative</td>
</tr>
<tr>
<td>7</td>
<td>Negative/Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>8</td>
<td>Positive/NP</td>
<td>Negative</td>
</tr>
<tr>
<td>9</td>
<td>Positive/NP</td>
<td>Negative</td>
</tr>
</tbody>
</table>

Abbreviations: IDT, intradermal test; NP, not performed; SPT, skin prick test.

* Patients 1 and 2 were exposed to the drug orally outside the context of a controlled challenge test and experienced an allergic reaction.
Controlled Oral Challenge Tests

Increasing doses of omeprazole (5, 10, and 20 mg), lansoprazole (3.25, 7.5, and 15 mg), or pantoprazole (5, 10, and 20 mg) were administered orally at 60-minute intervals until the therapeutic doses were reached or symptoms appeared.

Omeprazole was administered to the only patient with a negative skin test result. Four hours after ingestion of the final dose (cumulative 35 mg), the patient developed widespread urticaria and chest tightness, which resolved after treatment with methylprednisolone and dexchlorpheniramine. Two patients (1 and 2 in Table 2) with positive skin test results for omeprazole were exposed to the drug orally outside the context of a controlled challenge test and experienced an allergic reaction.

Lansoprazole was administered to all 9 patients until the therapeutic dose was reached. Eight showed good tolerance. Only 1 patient suffered widespread urticaria 1 hour after taking the final dose. She was a 39-year-old woman with dyspepsia and gastroesophageal reflux disease who experienced pruritus and generalized cutaneous eruption 60 minutes after ingestion of omeprazole and ketorolac. Skin tests were positive for omeprazole and negative for ketorolac, which was tolerated in a controlled challenge test. As ranitidine did not improve her digestive symptoms, a controlled challenge test with lansoprazole was carried out.

Only 3 patients were challenged with pantoprazole, and all of them developed pruritus and urticaria within less than 30 minutes after the second dose (cumulative 15 mg). This reaction resolved 60 minutes after treatment with methylprednisolone and dexchlorpheniramine. These 3 patients had tolerated lansoprazole. The results of the controlled challenge tests are shown in Table 2.

Discussion

We report 9 women diagnosed with allergy to omeprazole. The time course between the reaction and the ingestion of the drug, characteristics of the reaction, and skin test or challenge test results suggest an immunoglobulin E–mediated mechanism. There have been several reports of allergy to different PPIs [2-5,7-14,16-22]; however, to our knowledge, this is the largest published series.

Diagnosis of PPI allergy is not easy. On the one hand, many drugs are usually involved in the reaction, since PPI are frequently used in combination with antibiotics to eradicate *H pylori* or with NSAIDs for protection against gastric damage. On the other hand, these drugs are frequently used without medical prescription, and they are not recorded in the medical history. In our opinion, patients must always be asked whether they take PPI in order to avoid underdiagnosis and unplanned re-exposures.

The earliest reports base the diagnosis of PPI allergy on clinical data or challenge tests [2-4,8,11]. However, most authors [5,9,12,13,16] state that skin tests are useful diagnostic tools. In our series, 8 patients had positive skin test results for omeprazole and a challenge test was necessary to confirm the diagnosis in only 1 case. In this case, the reaction occurred later than in the other 8, a circumstance that had been reported elsewhere involving pantoprazole with a negative skin prick test and a positive oral challenge result [17,18]. Our results show that skin tests have high sensitivity and specificity.

Skin prick tests with lansoprazole were negative in all the cases and tolerance was confirmed in 8 of them. Only 1 patient developed an allergic reaction to lansoprazole in a controlled challenge test. However, 3 of our patients had positive skin tests to pantoprazole and another 2 patients challenged with this drug developed allergic reactions. Therefore, in most of our cases, lansoprazole was a valid alternative PPI, whereas the results obtained with pantoprazole provide evidence of a high rate of cross-reactivity. Nevertheless, we believe that skin tests and controlled oral challenge tests with lansoprazole are mandatory before offering it as a safe therapeutic alternative. The flow cytometric basophil activation test is a new test [19] that could improve the final diagnosis.

Previous reports describe different patterns of cross-reactivity between PPIs after skin prick or oral challenge tests: between omeprazole and lansoprazole confirmed by skin tests [5] (only 1 case in our group); between omeprazole, lansoprazole, and pantoprazole confirmed by skin tests [12,20] (none in our series); and between omeprazole and pantoprazole [21-23] (4 in our patients). Other authors suggest cross-reactivity between lansoprazole and rabeprazole [13,14]. PPIs are modified benzimidazoles with a pyridine ring, differing in that substitutions are present on both rings (Figure). Thus, omeprazole and pantoprazole have, respectively, a methoxy and a difluoromethoxy chain in their benzimidazole ring, whereas lansoprazole and rabeprazole have no modifications in that ring, but their pyridine rings have, respectively, a trifluoroethoxy and methoxypropoxy chain. Therefore, in
agreement with Perez Pimiento et al [14], we think that these analogous chemical structures are responsible for the high rate of cross-reactivity observed between omeprazole and pantoprazole and give support to the results obtained with our patients.

We present 9 patients with IgE-mediated allergy to omeprazole. In most cases, lansoprazole proved to be a good alternative treatment. We would like to highlight the importance of skin tests as diagnostic tools in PPI allergy. Furthermore, we underline the importance of an allergologic study (including skin and controlled challenge tests) before offering lansoprazole as a safe alternative to patients.

References


Manuscript received June 6, 2008; accepted for publication October 2, 2008.

Dr. Teófilo I. Lobera
C/ Gran Vía, 40 – 8ª Dcha
26005 Logroño
Spain
E-mail: tlobera@riojasalud.es